Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism

被引:24
|
作者
Shih, Jing-Wen [1 ,2 ]
Wang, Ling-Yu [3 ]
Hung, Chiu-Lien [3 ]
Kung, Hsing-Jien [1 ,3 ,4 ]
Hsieh, Chia-Ling [2 ]
机构
[1] Taipei Med Univ, Ctr Translat Med, Integrated Translat Lab, Taipei 11031, Taiwan
[2] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei 11031, Taiwan
[3] Univ Calif Davis, Ctr Comprehens Canc, Dept Biochem & Mol Med, Sacramento, CA 95817 USA
[4] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Miaoli County, Taiwan
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2015年 / 16卷 / 12期
基金
美国国家卫生研究院;
关键词
non-coding RNA; micro RNAs; long non-coding RNAs; castration-resistant prostate cancer; androgen receptor; cancer metabolism; POTENTIAL THERAPEUTIC TARGET; MITOXANTRONE PLUS PREDNISONE; IN-SITU HYBRIDIZATION; GROWTH-FACTOR-I; CIRCULATING MICRORNAS; DOWN-REGULATION; CELL-GROWTH; RECIPROCAL REGULATION; DEPRIVATION THERAPY; GENE-EXPRESSION;
D O I
10.3390/ijms161226138
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a bone-metastatic status with no cure. Understanding of the molecular mechanisms conferring resistance to androgen deprivation therapy has the potential to lead to the discovery of novel therapeutic targets for type of prostate cancer with poor prognosis. Progression to castration-resistant prostate cancer (CRPC) is characterized by aberrant androgen receptor (AR) expression and persistent AR signaling activity. Alterations in metabolic activity regulated by oncogenic pathways, such as c-Myc, were found to promote prostate cancer growth during the development of CRPC. Non-coding RNAs represent a diverse family of regulatory transcripts that drive tumorigenesis of prostate cancer and various other cancers by their hyperactivity or diminished function. A number of studies have examined differentially expressed non-coding RNAs in each stage of prostate cancer. Herein, we highlight the emerging impacts of microRNAs and long non-coding RNAs linked to reactivation of the AR signaling axis and reprogramming of the cellular metabolism in prostate cancer. The translational implications of non-coding RNA research for developing new biomarkers and therapeutic strategies for CRPC are also discussed.
引用
收藏
页码:28943 / 28978
页数:36
相关论文
共 50 条
  • [1] Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer
    Gao, Ke
    Li, Xiaoshun
    Ni, Jianxin
    Wu, Bin
    Guo, Jiaheng
    Zhang, Rui
    Wu, Guojun
    CANCER LETTERS, 2023, 566
  • [2] Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    Feng, Qin
    He, Bin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [3] Non-coding RNAs regulating androgen receptor signaling pathways in prostate cancer
    Lu, Ke
    Yu, Muyuan
    Chen, Yongchang
    CLINICA CHIMICA ACTA, 2021, 513 : 57 - 63
  • [4] Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer
    Reichert, Zachery R.
    Hussain, Maha
    CANCER JOURNAL, 2016, 22 (05): : 326 - 329
  • [5] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Graham, Laura
    Schweizer, Michael T.
    MEDICAL ONCOLOGY, 2016, 33 (05)
  • [6] Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
    Perner, Sven
    Cronauer, Marcus V.
    Schrader, Andres Jan
    Klocker, Helmut
    Culig, Zoran
    Baniahmad, Aria
    ONCOTARGET, 2015, 6 (34) : 35542 - 35555
  • [7] Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
    Coutinho, Isabel
    Day, Tanya K.
    Tilley, Wayne D.
    Selth, Luke A.
    ENDOCRINE-RELATED CANCER, 2016, 23 (12) : T179 - T197
  • [8] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Laura Graham
    Michael T. Schweizer
    Medical Oncology, 2016, 33
  • [9] Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other
    Alanazi, Ibrahim O.
    Al Shehri, Zafer S.
    Ebrahimie, Esmaeil
    Giahi, Hassan
    Mohammadi-Dehcheshmeh, Manijeh
    MOLECULAR CARCINOGENESIS, 2019, 58 (06) : 862 - 874
  • [10] Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
    Sharifi, Nima
    MOLECULAR ENDOCRINOLOGY, 2013, 27 (05) : 708 - 714